دورية أكاديمية
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
| العنوان: | IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. |
|---|---|
| المؤلفون: | Stathis, Anastasios, Pirosa, Maria Cristina, Orsucci, Lorella, Feugier, Pierre, Tani, Monica, Ghesquières, Hervé, Musuraca, Gerardo, Rossi, Francesca Gaia, Merli, Francesco, Guièze, Romain, Gyan, Emmanuel, Gini, Guido, Marino, Dario, Gressin, Remy, Morschhauser, Franck, Cavallo, Federica, Palombi, Francesca, Conconi, Annarita, Tessoulin, Benoît, Tilly, Hervé, Zanni, Manuela, Cabras, Maria Giuseppina, Capochiani, Enrico, Califano, Catello, Celli, Melania, Pulsoni, Alessandro, Angrilli, Francesco, Occhini, Ubaldo, Casasnovas, René-Olivier, Cartron, Guillaume, Devizzi, Liliana, Haioun, Corinne, Liberati, Anna Marina, Houot, Roch, Merli, Michele, Pietrantuono, Giuseppe, Re, Francesca, Spina, Michele, Landi, Francesco, Cavalli, Franco, Bertoni, Francesco, Rossi, Davide, Ielmini, Nicoletta, Borgo, Elena, Luminari, Stefano, Zucca, Emanuele, Thieblemont, Catherine |
| المصدر: | Stathis, Anastasios; Pirosa, Maria Cristina; Orsucci, Lorella; Feugier, Pierre; Tani, Monica; Ghesquières, Hervé; Musuraca, Gerardo; Rossi, Francesca Gaia; Merli, Francesco; Guièze, Romain; Gyan, Emmanuel; Gini, Guido; Marino, Dario; Gressin, Remy; Morschhauser, Franck; Cavallo, Federica; Palombi, Francesca; Conconi, Annarita; Tessoulin, Benoît; Tilly, Hervé; . (2024). IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. (In Press). Haematologica - the hematology journal Ferrata-Storti Foundation 10.3324/haematol.2023.283918 |
| بيانات النشر: | Ferrata-Storti Foundation |
| سنة النشر: | 2024 |
| المجموعة: | BORIS (Bern Open Repository and Information System, University of Bern) |
| مصطلحات موضوعية: | 610 Medicine & health |
| الوصف: | The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatment comprised an induction phase with chlorambucil 6 mg/m2/day orally on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and rituximab 375 mg/m2 intravenously on day 1 of weeks 1-4, and 1400 mg SC on weeks 9, 13, 17, and 21. Then, a maintenance phase followed with rituximab administered at 1400 mg SC every two months for two years. Of the 112 patients enrolled, 109 were evaluated for efficacy. The CR rates increased from 52% at the end of the induction phase to 70% upon completion of the maintenance phase. With a median follow-up of 5.8 years, the 5-year event-free, progression-free, and overall survival rates were 87% (95% CI, 78-92), 84% (95% CI, 75-89), and 93% (95% CI, 86-96), respectively. The most common grade ≥3 toxicities were neutropenia (33%) and lymphocytopenia (16%). Six patients experienced treatment-related serious adverse events, including fever of unknown origin, sepsis, pneumonia, respiratory failure, severe cerebellar ataxia, and fatal acute myeloid leukemia. The trial showed that subcutaneous rituximab did not improve the complete remission rate at the conclusion of the induction phase, which was the main endpoint. Nevertheless, SC maintenance might have facilitated long-term disease control, potentially contributing to enhanced event-free and progression-free survival. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://boris.unibe.ch/193175Test/ |
| الإتاحة: | https://doi.org/10.3324/haematol.2023.283918Test https://boris.unibe.ch/193175Test/ |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.CC9A575C |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |